LightSeed LLC

---

LightSeed LLC was initially established as a Delaware Corporation in 2006 (Entity ID:

06698443) and changed its name to LightSeed LLC in 2016.

LightSeed LLC is a biotechnology company that is developing technology to: 

1. Prevent cardiac toxicity from chemotherapy and radiation. 

Cardiac toxicity is a serious consequence of cancer therapies (Chemotherapies, Targeted therapies and Radiation).

https://www.nccn.org/patients/resources/life_with_cancer/managing_symptoms/cardiac_toxicity.aspx

2. Allow selective introduction for gene therapy at a single cell level.

LightSeed LLC integrates two type of technologies in order to provide more precise therapies for human disease. 

1. Precision gene therapy has been developed through a series of milestones illustrated to the left. Current development (H-L).

2. Cardioprotection from chemotherapy.

Cardiotoxicity from breast cancer therapies can be serious.  Seriousness ranges from overt clinical symptoms requiring urgent hospital admission, to an asymptomatic detectable structural change on cardiac imaging or new onset arrhythmia, to a measurable biomarker rise before symptomatic, structural or electrical change is detectable. 

•       The sub-types of cardiotoxicity occur as clinical decompensation in 2–4%, sub-clinical structural change in 9–11%, arrhythmia (e.g. AF) in >12%, and biomarker rise in 30–35% of cancer chemotherapy patients.  Cardiotoxicity, first observed in adult cancer patients as clinical congestive heart failure (CHF), characterized by pulmonary edema, fluid overload, and effort intolerance, has been known since the 1970s, with a cumulative doxorubicin dose-dependent incidence of CHF of 3%, 7%, and 18% at (400, 550, and 700 mg/m2). 
•      A further retrospective pooled analysis of three breast and lung cancer trials by Swain et al. documented higher rates of CHF – 4.7%, 26%, and 48% (400, 550 and 700 mg/m2). 
•          Further studies of biopsy-confirmed doxorubicin cardiomyopathy documented alarmingly poor prognosis – hazard ratio for fatal cardiotoxicity 3.46 and 50% mortality at two years. 
•     Sub-clinical cardiotoxicity is commonly defined on cardiac imaging as clinically asymptomatic left ventricular systolic dysfunction (LVSD) with a fall in left ventricular (LV) ejection fraction (EF) by >10% points to a value of EF < 50%. 
•     Cardiotoxic morbidity and mortality occur at higher numerical epirubicin doses than for doxorubicin. Dose-related NYHA class II or worse congestive heart failure (CHF) incidence occurred in 1.9% at 800 mg/m2, 4% at 900 mg/m2, and 15% at >1000 mg/m2 in a series of 469 epirubicin-treated breast cancer patients. 
•     Congestive Heart Failure occurring at a median onset of 57 days with overall 38% mortality and median survival of 162 days and 125 days if patients had received radiotherapy.

Anthracyclines can cause heart toxicity. Anthracyclines used to treat many types of cancers. Examples include some types of leukemia, lymphoma, sarcomas as well as bladder, bone, breast, head and neck, kidney, skin, stomach, and other cancers. Anthracyclines include:

Daunorubicin (Cerubidine®),

• Doxorubicin,
• Doxorubicin liposome injection (Doxil®),
• Epirubicin (Ellence®),
• Idarubicin (Idamycin® PFS), and
• Valrubicin (Valstar®)

Targeted therapy drugs that can cause damage to the heart include 

trastuzumab (Herceptin®), 

• bevacizumab (Avastin®), 
• lapatinib (Tykerb®), 
• sunitinib (Sutent®), 
• sorafenib (Nexavar®). 

These drugs are used in a variety of cancer types.

 Breast cancer (BCa) causes the death of >40,000 women in the USA and 410,000 women in the world annually. 20% to 30% of patients with early BCa will experience relapse with distant metastatic disease, with metastasis as the main cause of death. 

Patients with basal tumors, including Triple negative BCa (TNBC)(the absence of AR, ERa, and HER-2), have increased risk of metastasis and lower survival rate.